Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 50,439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Lung Cancer, Breast Cancer, Gynecologic Cancer
Interventions: Carevive PROmpt™; Other
Lead sponsor: Carevive Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Cancer Research Network; Other
Eligibility: Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: Plantation, Florida • Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: PRLX 93936; Drug
Lead sponsor: Prolexys Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 6
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Durham, North Carolina + 2 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Blood Collection During Standard of Care Treatment; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Smoking, Cigarette, Breastfeeding
Interventions: Integrated intervention of smoking cessation and breastfeeding, Attention placebo control; Behavioral
Lead sponsor: Xiaozhong Wen; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Myeloma
Interventions: Bortezomib, Carmustine, Etoposide, Cytarabine, Melphalan, Stem cell infusion; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Cancer
Interventions: SBRT 40.0 Gy, SBRT 42.5 Gy, SBRT 45.0 Gy, SBRT 47.5 Gy, SBRT 50.0 Gy, SBRT 52.5 Gy, SBRT 55.0 Gy, SBRT 57.5 Gy, SBRT 60.0 Gy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 57
States / cities: Peoria, Arizona • Scottsdale, Arizona • Burbank, California + 50 more

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: busulfan, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Non-Hodgkin
Interventions: Tositumomab and Iodine I 131 Tositumomab, Rituximab; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Walla Walla, Washington

Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions: AMXT1501, DFMO; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more

Conditions: Lymphoma, Follicular
Interventions: inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 17
States / cities: Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more

Conditions: Lymphoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions: Amifostine, Radiation Therapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 35 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions: PD-0332991; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: Embodied Conversational Agent, REDCap Survey; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cyst, Pancreatic Mucinous Cystic Neoplasm
Interventions: Tamoxifen 20mg; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Barrett's Esophagus, Gastroesophageal Reflux Disease
Interventions: Not listed
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: carboxyamidotriazole, placebo, quality-of-life assessment, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions: Nanvuranlat, Physician's Best Choice; Drug · Other
Lead sponsor: J-Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Duarte, California • Orange, California • Santa Monica, California + 15 more

Conditions: Older Adults, Anxiety, Depression, Cardiac Surgery, Orthopedic Surgery, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
Interventions: Behavioral Activation, Medication Optimization; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Endometrial Cancer, Gynecologic Cancer
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Head and Neck Cancer
Interventions: fluorouracil, gemcitabine hydrochloride, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: 18F-FDG, Breast-dedicated PET camera; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer
Interventions: Vaginal Cuff Brachytherapy; Radiation
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Pediatric Brain Tumor, Glioma, Anaplastic Astrocytoma, Medulloblastoma, Glioblastoma
Interventions: Valproic Acid; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 1 Year and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.

An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Lung and Breast Cancer Prevention by an Integrated Intervention of Maternal Smoking Cessation and Breastfeeding

Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Oral AMXT 1501 Dicaprate in Combination With DFMO

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Amifostine for Head and Neck Irradiation in Lymphoma

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Improving PRO for Patients With Cancer Using ECAs and Data Visualization

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Behavioral Activation and Medication Optimization for Perioperative Mental Health Feasibility Study

Diet, Hepcidin, and Chemotherapy RDI

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer

Valproic Acid in Childhood Progressive Brain Tumors